IL-2 Market Projected to Hit USD 4 Billion by 2034

A Robust and Diverse IL-2 Pipeline

The IL-2 pipeline continues to expand, with multiple clinical-stage assets addressing both cancer and autoimmune indications. Leading developers include Mural Oncology (Nemvaleukin Alfa/ALKS 4230), Nektar Therapeutics (Rezpegaldesleukin/NKTR-358), Corvus Pharmaceuticals (Soquelitinib), Cue Biopharma (CUE-101), Krystal Biotech (KB707), Philogen (Darleukin), ILTOO Pharma (ILT-101), Innovent Biologics (IBI-363), Merck Sharp & Dohme (MK-6194), Synthekine (STK-012), and Werewolf Therapeutics (WTX-124).

From a revenue perspective, moderate-to-severe atopic dermatitis represents the largest opportunity in the 7MM, with nearly 39 million cases in 2024, a figure expected to grow through 2034. Additionally, the US alone accounted for approximately 1.7 million eligible NSV cases in 2024.

While the global IL-2 landscape is dominated by US and European innovators, Japan currently represents the most active Asia-Pacific market with company-sponsored IL-2 clinical programs.

Japan: Eisai Leads Regional IL-2 Development

Eisai Co., Ltd. (Japan) has emerged as the leading Asian sponsor of IL-2-based therapies through the development of E7777, a next-generation IL-2–diphtheria toxin fusion protein designed to selectively target IL-2 receptor–expressing malignant T cells.

• Drug Candidate: E7777
  
  
• Mechanism of Action: Recombinant fusion protein combining IL-2 with diphtheria toxin fragments, inducing cytotoxicity in IL-2R–positive tumor cells
• Clinical Phases: Phase I and Phase II
• Key Indications: Relapsed/refractory PTCL and CTCL
• Clinical Trial IDs: NCT01401530 (Phase I), NCT02676778 (Phase II)

See top IL-2 market contenders @ Interleukin-2 Market Report - https://www.delveinsight.com/report-store/interleukin-2-market-forecast?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Clinical studies conducted in Japan demonstrated meaningful objective response rates with a manageable safety profile, supporting regulatory approval. In March 2021, E7777 received approval in Japan for relapsed/refractory PTCL and CTCL, positioning it as a key IL-2 therapy in the Asian oncology market and complementing the global momentum of LYMPHIR.

As of the latest clinical trial registries, no South Korean or Taiwanese biopharmaceutical companies are actively sponsoring or co-sponsoring Phase I–III clinical trials where IL-2 or IL-2-engineered biologics are the primary investigational agents. While several companies in these regions are active in immuno-oncology and cytokine-modulating research, IL-2 programs remain largely investigator-initiated rather than industry-sponsored.

Spotlight on Leading IL-2 Innovators

• Nemvaleukin Alfa (Mural Oncology): A receptor-biased IL-2 agonist fusion protein designed to enhance anti-tumor immunity with reduced systemic toxicity. Phase II/III programs in melanoma, mucosal melanoma, and platinum-resistant ovarian cancer are ongoing, with key data readouts expected in 2025. Peak sales are projected near USD 140 million by 2034.
  
  
• Soquelitinib (Corvus Pharmaceuticals): An oral ITK inhibitor targeting T-cell signaling pathways, under Phase III evaluation for relapsed/refractory PTCL and Phase I for atopic dermatitis. The drug received Fast Track and Orphan Drug Designations from the FDA in 2024, with a potential combined market of USD 360 million by 2034.
  
  
• Rezpegaldesleukin (Nektar Therapeutics): A T-regulatory cell–biased IL-2 agonist in Phase II for atopic dermatitis and alopecia areata, offering a differentiated, self-administered, low-toxicity approach. Peak sales are projected to reach USD 930 million by 2034.
  
  
• KB707 (Krystal Biotech): A novel gene therapy delivering IL-2 and IL-12 directly to tumors via intratumoral or inhaled administration, showing promising response rates in NSCLC and melanoma.
  
  
• CUE-101 (Cue Biopharma): A precision IL-2-based immunotherapy targeting HPV16-positive HNSCC, with Fast Track designation and encouraging combination data alongside PD-1 inhibitors.